GlassScriptPhysician profile
Laura Marbun
NPI 1548718935
$3,492.35
in general payments reported to CMS, 2019-2025
21 companies · $2,825 in 2025
The $2,825 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $75.30 · 2024: $592 · 2025: $2,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,276 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,276.37 |
| Education | $215.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,068.21 | 2024-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $680.77 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $362.60 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $219.84 | 2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $213.84 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Acadia Pharmaceuticals INC | $172.89 | 2025 | Nuplazid |
| Janssen Pharmaceuticals, INC | $119.58 | 2025 | Spravato |
| Axsome Therapeutics, INC. | $119.23 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $116.51 | 2024-2025 | Loreev Xr |
| Next Science LLC | $87.46 | 2023-2024 | Surgx, Blastx, Xperience |
| Noven Therapeutics, LLC | $68.83 | 2025 | Xelstrym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.54 | 2024-2025 | Caplyta |
| Abbvie INC. | $45.07 | 2025 | |
| Hydrofera LLC | $24.50 | 2024 | Hydrofera Blue |
| Kci USA, INC. | $22.52 | 2023 | Prevena, Promogran Prisma, Activ.A.C. |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $21.80 | 2025 | Spravato |
| Eisai INC. | $21.47 | 2025 | |
| Kerecis Limited | $20.04 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Vanda Pharmaceuticals INC. | $18.40 | 2025 | Fanapt, Hetlioz |
| Exact Sciences Corporation | $16.65 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $16.60 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Marbun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.